tgindex

Cardiology Updates

описание

All the atest articles, research and news from worlds leading Cardiology Journals. Discussion group https://t.me/Professional_Medical_Discussion

← к каналу@Cardiology_Updates
19 173
подписчиков
Охват к подписчикам
16,4%
ERR
Реакции к просмотрам
0,13%
153 на 50 постов
Пересылки к просмотрам
0,18%
213
Постов в день
0,3
всего 50

Где отзываются чаще

доля реакций к просмотрам
  • 17 нояб. 2024 г.🔴 CLEAR Trial: Routine Spironolactone in Acute Myocardial Infarction 🔍 Background Spironolactone’s benefit after myocardial infarction (MI) is uncertain. Past studies show mineralocorticoid receptor antagonists reduce mortality in MI with heart failure. 🧪 Methods A multicentre, 2x2 factorial trial with 7062 post-PCI MI patients, assigned to spironolactone or placebo. Primary outcomes: • Death from cardiovascular causes or new/worsening heart failure • Composite of MI, stroke, new/worsening heart failure, or cardiovascular death 📉 Results • No significant reduction in cardiovascular events (HR: 0.91, P=0.51) • Serious adverse events: 7.2% (spironolactone) vs. 6.8% (placebo) Conclusion Spironolactone did not reduce cardiovascular death or heart failure events post-MI. Full details: https://www.nejm.org/doi/full/10.1056/NEJMoa2405923 #medicalresearch @The_NEJM0,75%
  • 17 нояб. 2024 г.🔵 BPROAD Trial: Intensive BP Control in Type 2 Diabetes 🩺 🔹 Background Optimal BP targets in Type 2 diabetes remain uncertain. 🔹 Methods • Enrolled 12,821 patients (age ≥50) across 145 sites in China • Randomised to BP targets: <120 mmHg (intensive) vs <140 mmHg (standard) • Follow-up: median 4.2 years 🔹 Results • Primary outcomes: 1.65 events/100 person-years (intensive) vs 2.09 events (standard) • HR: 0.79 (P<0.001) ⚠️ Higher hypotension & hyperkalemia in intensive group. Conclusions: Intensive BP control (<120 mmHg) significantly reduces major CV events in T2DM. For full article: https://www.nejm.org/doi/full/10.1056/NEJMoa2412006 #medicalresearch @Updates_in_Medicine0,57%
  • 18 нояб. 2024 г.🔴 CLEAR Trial: Colchicine in Acute Myocardial Infarction 🔍 Background Inflammation is linked to adverse cardiovascular events. Colchicine has shown promise in reducing cardiovascular event risk. 🧪 Methods A multicentre, 2x2 factorial trial with 7062 MI patients assigned to colchicine or placebo. Primary outcome: • Composite of cardiovascular death, recurrent MI, stroke, or unplanned revascularisation 📉 Results • No significant difference in primary outcome events (HR: 0.99, P=0.93) • Greater reduction in C-reactive protein at 3 months with colchicine • Higher diarrhoea rates in colchicine group (10.2% vs. 6.6%) Conclusion Colchicine did not reduce major cardiovascular events post-MI. https://www.nejm.org/doi/full/10.1056/NEJMoa2405922 #medicalresearch @The_NEJM0,56%
  • 15 окт. 2024 г.SGLT2 Inhibitors Associated With Better Survival in PAH (Original Article) 🫀 Study from CHEST 2024 shows that SGLT2 inhibitors (dapagliflozin, empagliflozin) are linked with reduced mortality in pulmonary arterial hypertension (PAH). 📉 1-year mortality dropped from 15.5% to 8.1% 📉 5-year mortality dropped from 25% to 14.6% 💡 Potential mechanisms include anti-inflammatory effects and vascular remodeling, but more trials are needed before these findings can change clinical practice. https://www.medscape.com/viewarticle/sglt2-inhibitors-associated-better-survival-pah-2024a1000idi?ecd=a2a #MedicalResearch @Updates_in_Medicine0,55%
  • 15 февр. 2025 г.Colchicine & Spironolactone in Acute MI: No Significant Benefit 🚫 🔑 Key Findings: • Colchicine: No reduction in the composite primary outcome (cardiovascular death, recurrent MI, stroke, or unplanned revascularisation). • Results: 9.1% event rate in the colchicine group vs. 9.3% in the placebo group. • Hazard Ratio: 0.99 (95% CI, 0.85–1.16; P=0.93) • Spironolactone: No significant reduction in death from cardiovascular causes or new/worsening heart failure. • Results: 1.7 events/100 patient-years in spironolactone vs. 2.1 in placebo. • Hazard Ratio: 0.91 (95% CI, 0.69–1.21; P=0.51) 🩺 Clinical Implication: Routine use of colchicine and spironolactone post-MI does not improve outcomes. 🔗 Original Articles: 📄 Colchicine: https://doi.org/10.1056/NEJMoa2405922 📄 Spironolactone: https://doi.org/10.1056/NEJMoa2405923 #medicalresearch @Updates_in_Medicine0,41%
  • 25 окт. 2024 г.⚫️ Finerenone in Heart Failure with Preserved or Mildly Reduced Ejection Fraction Link: https://www.nejm.org/doi/full/10.1056/NEJMoa2407107 HFpEF and HFrEFhas limited treatments with proven mortality benefits. But finerenone is changing that! 🌟 📚 Background: Finerenone’s efficacy in heart failure with mildly reduced or preserved ejection fraction was uncertain. 🩺 Methods: Patients were randomly assigned to receive finerenone or placebo in a double-blind trial. 📊 Results: Finerenone significantly reduced total worsening heart failure events and cardiovascular deaths compared to placebo. ▪️Conclusions: Finerenone is effective in reducing heart failure worsening and cardiovascular deaths in patients with mildly reduced or preserved ejection fraction. #medicalresearch @Updates_in_Medicine0,38%
  • 19 нояб. 2024 г.🔴 SUMMIT Trial: Tirzepatide for HFpEF with Obesity 🔍 Background Obesity raises heart failure with preserved ejection fraction (HFpEF) risk. Tirzepatide, a GLP-1 and GIP agonist, induces weight loss, but its cardiovascular effects were unclear. 🧪 Methods 731 HFpEF patients (BMI ≥30) randomised to tirzepatide or placebo for 52 weeks. Primary outcomes: • Composite of CV death or worsening HF events • Kansas City Cardiomyopathy Questionnaire (KCCQ-CSS) score change 📉 Results • CV death/worsening HF: 9.9% (tirzepatide) vs. 15.3% (placebo) (HR: 0.62; P=0.026) • Improved quality of life (KCCQ-CSS difference: 6.9; P<0.001) • Higher GI adverse events in tirzepatide (6.3% vs. 1.4%) Conclusion Tirzepatide reduced HF events and enhanced health status in HFpEF with obesity. https://www.nejm.org/doi/full/10.1056/NEJMoa2410027 #medicalresearch @The_NEJM0,37%
  • 15 нояб. 2024 г.💎 Metformin in Advanced CKD: To Stop or Continue? 🔍 🔗 Original Article • Study Overview: Scottish cohort study compared outcomes for stopping vs. continuing metformin in stage 4 CKD (eGFR <30 mL/min). • Key Findings: • Continuing metformin was associated with higher 3-year survival. • No significant increase in major adverse cardiovascular events (MACE) with continued use. • Increased respiratory-related mortality in those who stopped metformin. • Conclusions: Continuing metformin could benefit survival in patients with advanced CKD. Further RCTs are essential. #medicalresearch @Updates_in_Medicine0,35%
  • 19 янв. 2025 г.🔴 EARLY TAVR Trial: Transcatheter Aortic-Valve Replacement for Asymptomatic Severe Aortic Stenosis 📌 Key Findings: • Early TAVR reduced composite events of death, stroke, or unplanned cardiovascular hospitalisations by 50% (HR 0.50; 95% CI 0.40–0.63). • TAVR group: 26.8% primary events vs 45.3% in surveillance. • Conclusions: Among asymptomatic severe aortic stenosis patients, early TAVR was superior to clinical surveillance in reducing major adverse cardiovascular events. 🔗 Full study: https://doi.org/10.1056/NEJMoa2405880 #medicalresearch @The_NEJM0,26%
  • 19 нояб. 2024 г.🔴 OPTION Trial: Left Atrial Appendage Closure (LAAC) after AF Ablation 🔍 Background Oral anticoagulation is standard after AF ablation for high stroke risk patients, but LAAC offers a mechanical alternative. Evidence on its use post-ablation is limited. 🧪 Methods 1,600 AF patients with high CHA2DS2-VASc scores were randomised to LAAC or anticoagulation post-ablation. Primary outcomes: • Safety: Non–procedure-related major bleeding • Efficacy: Composite of death, stroke, or systemic embolism (36 months) 📉 Results • LAAC had lower non-procedure-related bleeding (8.5% vs. 18.1%; P<0.001) • Comparable rates of death, stroke, or embolism (5.3% vs. 5.8%; P<0.001 for noninferiority) • Device-related complications in 23 patients Conclusion LAAC post-AF ablation showed lower bleeding risk and was noninferior to anticoagulation in major outcomes. https://www.nejm.org/doi/full/10.1056/NEJMoa2408308 #medicalresearch @The_NEJM0,23%
  • 15 окт. 2024 г.💊 Beta-Blocker After Myocardial Infarction: Continue or Stop? 🔹 Study: Multicenter trial with 3,698 patients across France. 🔹 Objective: To assess the safety of stopping beta-blockers after a heart attack to improve quality of life. 🔹 Methods: • Patients randomized into two groups: one continued beta-blockers, the other stopped. • Focused on patients with a left ventricular ejection fraction of at least 40%. 🔹 Results: • Cardiovascular events occurred in 23.8% of patients who stopped beta-blockers vs. 21.1% who continued. • Risk difference: 2.8%. • No improvement in quality of life for those who stopped beta-blockers. 🔸 Conclusion: Stopping beta-blockers wasn’t as safe as continuing them. Original Article - https://www.nejm.org/doi/full/10.1056/NEJMoa2404204 #medicalresearch @Updates_in_Medicine0,21%
  • 5 мар. 2025 г.🟢 Research Pearls 🔸 Engineered Heart Muscle Reinvigorates Failing Hearts Heart muscle grafts from induced pluripotent stem cells improved cardiac function in rhesus macaques with heart failure, with promising data from a human patient. Nature Medicine | February 2025 🔗 https://doi.org/10.1038/d41591-025-00013-z #medicalresearch @Updates_in_Medicine0,21%